>

Michael McMullen - Agilent Technologies CEO

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:6em;padding-top: 0px;;'>A</div>
A -- USA Stock  

Fiscal Quarter End: April 30, 2020  

  CEO
Mr. Michael R. McMuller is President, Chief Executive Officer, Director of Agilent Technologies, Inc. Mr. McMullen has served as our Chief Executive Officer since March 2015 and as President since September 2014. From September 2014 to March 2015 he also served as our Chief Operating Officer. From September 2009 to September 2014 he served as Senior Vice President, Agilent and President, Chemical Analysis Group. Prior to that, he served in various capacities for Agilent including as our Vice President and General Manager of the Chemical Analysis Solutions Unit of the Life Sciences and Chemical Analysis Group and as Country Manager for our China, Japan and Korea Life Sciences and Chemical Analysis Group. Prior to that, Mr. McMullen served as the Controller for the HewlettPackard Company and Yokogawa Electric Joint Venture from July 1996 to March 1999. Since September 2018, Mr. McMullen has served as a member of the Board of Directors of Coherent, Inc. r. McMullen has broad and deep experience with the company and its businesses having been an employee of the company and its predecessor, HewlettPackard, for over 20 years. During the course of his career, he has developed considerable expertise in, and indepth knowledge of, our businesses from the perspective of an individual contributor and at numerous levels of management. This perspective gives valuable insight to our board.
Age: 57  CEO Since 2015      
408 345-8474  www.agilent.com

Michael McMullen Latest Insider Activity

Management Efficiency

The company has return on total asset of 0.11 % which means that for every 100 dollars spent on asset it generated profit of $0.11. This is way below average. Similarly, it shows return on equity (ROE) of 0.17 % implying that it made 0.17 on every $100 invested by shareholders.
The company has accumulated 2.41 B in total debt with debt to equity ratio (D/E) of 50.6 implying that the company may be unable to produce cash to meet its debt commitments. Agilent Technologies has Current Ratio of 1.5 which is considered satisfactory as compared to similar companies.

Similar Executives

Found 13 records

CEO Since

Stephen LinthwaiteFluidigm Corporation
2016
Gary HuffLaboratory Corporation Of Ameri
2017
Christopher LinthwaiteFluidigm Corporation
2016
James BoyleLaboratory Corporation Of Ameri
N/A
Gajus WorthingtonFluidigm Corporation
2016
Kevin SayerDexCom
2018
John RatliffLaboratory Corporation Of Ameri
2019
Rui ArashiyamaGlobal Cord Blood Corporation
N/A
Deborah TannerLaboratory Corporation Of Ameri
2015
Adam SchechterLaboratory Corporation Of Ameri
2019
Paul KirchgraberLaboratory Corporation Of Ameri
2019
Yue DengGlobal Cord Blood Corporation
N/A
Helmy EltoukhyGuardant Health
2017

Company Summary

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company was founded in 1999 and is headquartered in Santa Clara, California. Agilent Technologies operates under Diagnostics Research classification in USA and is traded on BATS Exchange. It employs 16300 people.Agilent Technologies (A) is traded on BATS Exchange in USA. It is located in 5301 Stevens Creek Blvd., Santa Clara, CA 95051, United States and employs 16,300 people. Agilent Technologies is listed under Measuring and Control Equipment category by Fama And French industry classification.

Agilent Technologies Leadership Team

Daniel Podolsky, Independent DirectorView
Hans Bishop, Independent DirectorView
George Scangos, Independent DirectorView
Sue Rataj, Independent DirectorView
Jacob Thaysen, Senior Vice President, President - Life Sciences and Applied Markets GroupView
Samraat Raha, Senior Vice President, President - Diagnostics and Genomics GroupView
Mark Doak, Senior Vice President, President - Agilent CrossLab GroupView
Paul Clark, Independent DirectorView
Mala Anand, Independent DirectorView
Robert McMahon, Chief Financial Officer, Senior Vice PresidentView
Ankur Dhingra, Investor RelationsView
Hajime Tada, Interim General CounselView
James Cullen, Independent Non-Executive Chairman of the BoardView
Michael McMullen, CEO and President Director and Member of Executive CommitteeView
Patrick Kaltenbach, Sr. VP and President of Life Sciences and Applied Markets Group (LSAG) Bus. UnitView
Rodney Gonsalves, Chief Accounting Officer, Vice President, Corporate ControllershipView
Henrik AncherJensen, Senior Vice President and Presidentident - Order FulfillmentView
Dow Wilson, Independent DirectorView
Heidi Kunz, Independent DirectorView
Dominique Grau, Senior Vice President - Human ResourcesView
Heidi Fields, Independent DirectorView
Michael Tang, Senior Vice President General Counsel, SecretaryView
Alicia Rodriguez, Vice President - Investor RelationsView
Tadataka Yamada, Independent DirectorView
Didier Hirsch, CFO and Sr. VPView
Boon Koh, Non-Executive Independent Chairman of the BoardView
Robert Herbold, Independent DirectorView

Stock Performance Indicators

Did you try this?

Run Idea Breakdown Now

   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module

Agilent Technologies Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Agilent Technologies and Global Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.